Published in Drug Week, March 31st, 2006
Full year sales from continuing operations were $699.7 million, which includes $106.6 million from businesses acquired in 2005, compared to $541.6 million in 2004. Net income from continuing operations for the year was $45.2 million, or $1.39 per diluted share, compared to $33.5 million, or $1.09 per diluted share in 2004.
Sales from continuing operations were $195.6 million in the fourth quarter,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.